SCHEMBL26098752

SCHEMBL26098752

COc1cc2ncnc(-c3ccc(NC(=O)Cc4ccc(F)cc4)cc3)c2cc1OC(C)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 11/20 0.54
▸ FLT4 P35916 8/20 0.54
▸ FLT3 P36888 6/20 0.51
▸ CSF1R P07333 3/20 0.51
▸ KIT P10721 1/20 0.50
▸ MET P08581 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ KDR P35968 4/20 0.48
▸ PDE10A Q9Y233 1/20 0.48
▸ PDGFRA P16234 1/20 0.47
▸ EGFR P00533 1/20 0.46
▸ HDAC1 Q13547 2/20 0.46
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30394508 1.00 PDGFRB (0.54) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL26102256 0.88 PDGFRB (0.51) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL30394637 0.85 KDR (0.55) PDGFRBFLT4FLT3CSF1RKDR
SCHEMBL26535641 0.85 KDR (0.55) PDGFRBFLT4FLT3CSF1RKDR
SCHEMBL30891799 0.80 SMN1; SMN2 (0.48) PDGFRBSMN1; SMN2PDGFRA
SCHEMBL30394611 0.79 KDR (0.54) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL29238215 0.79 KDR (0.54) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL26102182 0.79 KDR (0.51) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL26102818 0.79 EGFR (0.54) PDGFRBFLT4FLT3CSF1RKIT
SCHEMBL26102366 0.79 KDR (0.51) PDGFRBFLT4FLT3CSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB PDGFRB 3/4885FLT4 19/4885FLT3 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback